natgillin/translations-raw huggingface dataset:
o One vial adapter (2) o One vial for paediatric use of Humira for injection (3) o Two alcohol pads (4) o One needle (5) 
o eno 1 ml brizgo (1) o en adapter za vialo (2) o eno vialo zdravila Humira za injiciranje za otroke (3) o dva alkoholna zloženca (4) o eno iglo (5)
• facial oedema (swelling of the face) associated with allergic reactions 
• edem obraza (otekanje obraza) povezan z alergijskimi reakcijami
You may notice a spot of blood at the injection site. 
Na mestu injiciranja se lahko pojavi kapljica krvi.
Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or more. 
Zdravilo Humira so raziskali pri 9506 bolnikih v kontroliranih in odprtih preskušanjih, ki podpirajo vlogo za pridobitev dovoljenja za promet in so trajala do 60 mesecev ali več.
Point the white arrow toward the injection site (thigh or abdomen). 
Belo puščico usmerite proti mestu injiciranja (stegno ali trebuh).
Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study in which Humira 40mg was administered every week. 
Bolniki, vključeni v študiji HS-I in HS-II, so bili primerni za vključitev v odprto podaljšano študijo, v kateri so prejemali zdravilo Humira 40 mg vsak teden.
The white needle sleeve will move down over the needle and lock into place over the needle tip. 
Beli tulec igle se bo pomaknil navzdol prek igle in se bo zaskočil nad njeno konico.
Steroid-free remission for ≥ 90 days 
Remisija brez steroidov za ≥ 90 dni a
These infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other opportunistic infections and sepsis that may, in rare cases, be life-threatening. 
Te okužbe so lahko resne in vključujejo tuberkulozo, okužbe, ki jih povzročijo virusi, glive, paraziti ali bakterije ali druge oportunistične okužbe in sepso, in so lahko v redkih primerih smrtno nevarne.
Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs). 
Zdravilo Humira se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), steroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders. 
b Bolniki, ki izpolnjujejo merila, določena v protokolu za izgubo odziva ali brez izboljšanja, so bili izključeni iz študij in so še šteli pod bolnike brez odgovora (“nonresponders”).
• feeling weak or tired 
• občutek šibkosti ali utrujenosti
Amongst those who responded (Pediatric ACR 30) at Week 24 (n=27 out of 30 patients), the Pediatric ACR 30 responses were maintained for up to 60 weeks in the OLE phase in patients who received Humira throughout this time period. 
Med tistimi, ki so se odzvali (Pediatric ACR 30) 24. teden (n = 27 od 30 bolnikov), se je odziv Pediatric ACR 30 v odprti podaljšani fazi ohranil do 60 tednov pri bolnikih, ki so med tem celotnim obdobjem prejemali zdravilo Humira.
Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study UV I) or Week 2 (Study UV II) 
Slika 2: Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v ali po 6. tednem (študija UV I) ali 2. tednu (študija UV II)
a 40 
Med njimi 40
Subjects (n=215, 54.7%) who failed to achieve ASAS 20 at Weeks 12, or 16 or 20 received early escape open-label adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses. 
Preiskovanci (n = 215, 54,7 %), ki 12. ali 16. ali 20. teden niso dosegli ASAS 20, so začeli v predčasni odprti fazi dobivati 40 mg adalimumaba vsak drugi teden subkutano, v poznejših statističnih analizah dvojno slepe faza pa so bili obravnavani kot neodzivni bolniki.
If you forget to use Humira 
Če ste pozabili uporabiti zdravilo Humira
Age Group 
Starostna skupina
• Do not inject into skin that is sore, bruised, red, hard, scarred, has stretch marks, or areas with psoriasis plaques 
• Ne injicirajte v kožo, ki je ranjena, obtolčena, rdeča, zatrdela, brazgotinasta, s strijami ali v predele, kjer je prisotna luskavica v plakih
To listen to or request a copy of this leaflet in <Braille>, <large print> or <audio>, please contact the local representative of the Marketing Authorisation Holder. 
Če želite poslušati ali zaprositi za kopijo tega navodila v <Braillovi pisavi>, <velikem tisku> ali
Physicians should exercise caution when considering the use of Humira in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo zdravila Humira je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
No studies have been conducted that include patients with a history of malignancy or in whom treatment with Humira is continued following development of malignancy. 
Študij, ki bi vključevale bolnike z anamnezo malignoma ali bolnike, pri katerih bi se zdravljenje z zdravilom Humira nadaljevalo po pojavu malignoma, ni bilo.
There is limited experience in the initiation of treatment with Humira alone. 
O začetku zdravljenja samo z zdravilom Humira so izkušnje omejene.
• If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice about taking this medicine. 
• Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
• It is normal to see a few drops of liquid come out of the needle 
• Normalno je, če iz igle prikaplja nekaj kapljic tekočine.
The decision to stop using Humira should be discussed with your doctor. 
O odločitvi, da bi prenehali uporabljati zdravilo Humira, se morate posvetovati s svojim zdravnikom.
Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with adolescent HS, and paediatric patients ≥ 40 kg with CD). 
Populacijsko farmakokinetično in farmakokinetično/farmakodinamično modeliranje in simulacija so za adalimumab napovedali primerljivo izpostavljenost in učinkovitost pri bolnikih, zdravljenih z 80 mg vsak drugi teden v primerjavi s 40 mg vsak teden (vključno z odraslimi bolniki z RA, HS, UC,
In addition, no malignancies were observed in 192 paediatric patients with an exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn's disease. 
Poleg tega niso opazili nobenega malignoma tudi pri 192 pediatričnih bolnikih, ki so bili izpostavljeni 498,1 bolnikov let med študijami z zdravilom Humira pri pediatričnih bolnikih s Crohnovo boleznijo.
Patients who achieved sustained remission for at least 12 weeks (N=305) (ASDAS < 1.3 at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either continued treatment with Humira 40 mg eow (N=152) or placebo (N=153) for an additional 40 weeks in a double-blind, placebo-controlled period (total study duration 68 weeks). 
Bolniki, ki so v odprti fazi dosegli trajno remisijo za vsaj 12 tednov (N = 305) (ASDAS < 1,3 v 16., 20., 24. in 28. tednu), so bili nato randomizirani tako, da so prejemali bodisi nadaljevalno zdravljenje z zdravilom Humira 40 mg vsak drugi teden (N = 152) ali placebo (N = 153) dodatnih 40 tednov v dvojno slepem, s placebom kontroliranem obdobju (celotno trajanje študije 68 tednov).
After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to 15 ml/hour, the distribution volume (Vss) ranged from 5 to 6 litres and the mean terminal phase half-life was approximately two weeks. 
15 ml/uro, volumen distribucije (Vss) od 5 do 6 litrov in povprečni razpolovni čas terminalne faze približno dva tedna.
If the white plunger rod is pulled completely out of the syringe, discard the syringe and contact your Humira provider for a replacement. 
Če beli nosilec bata potegnete popolnoma iz brizge, brizgo zavrzite in se z dobaviteljem zdravila
You should continue to inject Humira for as long as your doctor has told you. 
Nadaljevati morate z injiciranjem zdravila Humira tako dolgo, kot vam je naročil zdravnik.
In rheumatoid arthritis, methotrexate is continued while using Humira. 
Pri revmatoidnem artritisu se uporaba metotreksata med uporabo zdravila Humira nadaljuje.
This medicinal product contains less than 1 mmol of sodium (23 mg) per 0.8 ml dose, i.e. essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) v 0,8 ml odmerku, kar v bistvu pomeni ‘brez natrija'.
• heart attack 
• srčni napad
• If your child is pregnant, thinks she may be pregnant or is planning to have a baby, ask her doctor for advice about taking this medicine. 
• Če je vaš otrok noseč, misli, da je noseč ali načrtuje nosečnost, se glede uporabe tega zdravila posvetujte z otrokovim zdravnikom.
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for antibodies against double-stranded DNA, further treatment with Humira should not be given (see section 
Če se bolniku po zdravljenju z zdravilom Humira pojavijo simptomi, ki nakazujejo lupusu podobni sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom Humira ne sme nadaljevati (glejte poglavje 4.8).
Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX (Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). 
Značilno izboljšanje od izhodišča do 16. tedna se je v primerjavi s placebom (študiji I in II) in metotreksatom (študija II) izkazalo v dermatološkem indeksu kakovosti življenja (DLQIDermatology Life Quality Index).
Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks of rescue therapy with Humira, out of which 37 (56.9%) had regained remission (ASDAS < 1.3) after 12 weeks of restarting the open-label treatment. 
Med 68 bolniki iz skupine namenjene prenehanju zdravljenja pri katerih je prišlo do ponovnega zagona bolezni, jih je 65 zaključilo 12 tednov trajajoče rešilno zdravljenje z zdravilom Humira, od tega jih je 37 (56,9 %) po 12 tednih ponovne odprte faze zdravljenja ponovno doseglo remisijo (ASDAS < 1,3).
The active ingredient in Humira, adalimumab, is a human monoclonal antibody. 
Učinkovina v zdravilu Humira, adalimumab, je humano monoklonsko protitelo.
• musculoskeletal pain. 
• mišičnoskeletna bolečina.
If you are unsure, contact your doctor. 
Če niste prepričani, se posvetujte s svojim zdravnikom.
Improved physical function continued during the open label extension up to Week 136. 
Izboljšanje telesnega delovanja je trajalo še med odprto nadaljevalno študijo do 136. tedna.
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II. 
Uporabo zdravila Humira 40 mg vsak drugi teden so pri bolnikih z zmernim do hudim aktivnim psoriatičnim artritisom proučili v dveh s placebom kontroliranih študijah, študijah pri psoriatičnem artritisu I in II.
Keep this Patient Reminder Card with you or your child. 
To opozorilno kartico za bolnika imejte pri sebi ali jo naj ima pri sebi vaš otrok.
• Prepare the needle by partially peeling the package open from the end closest to the yellow syringe connector. 
• Pripravite iglo: delno odprite njeno ovojnino tako, da ga odlepite od konca, ki je najbližji rumenemu konektorju za brizgo.
Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), including adalimumab in the post marketing setting. 
Med obdobjem trženja so bili opisani malignomi (nekateri s smrtnim izidom) pri otrocih, mladostnikih in mladih odraslih (starih do 22 let), ki so dobivali antagoniste TNF, vključno z adalimumabom (začetek zdravljenja v starosti ≤ 18 let).
You will see a yellow indicator move into the window during the injection. 
Med injiciranjem boste videli pomikanje rumenega kazalnika v okence.
The active substance is adalimumab. 
Učinkovina je adalimumab.
This medicine has been prescribed for your child only. 
- Zdravilo je bilo predpisano samo vašemu otroku in ga ne smete dajati drugim.
Some of those patients were also treated with azathioprine or 6mercaptopurine. 
Nekateri od teh bolnikov so bili zdravljeni tudi z azatioprinom ali 6-merkaptopurinom.
• allergic reactions (including seasonal allergy) 
• alergijske reakcije (vključno s sezonskimi alergijami)
The primary endpoint was the percent change from Baseline to Week 12 in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of62.6% (median percent change -88.9%) in patients in the Humira group compared to -11.6% (median percent change -50.0%) in patients in the placebo group. 
Primarni opazovani dogodek je bil odstotek spremembe od izhodiščne vrednosti do 12. tedna v številu aktivnih sklepov z artritisom (oteklina, ki ni nastala zaradi deformacije ali sklepi z zmanjšano gibljivostjo ter bolečino in/ali občutljivostjo); slednji je bil dosežen s povprečnim zmanjšanjem za -62,6 % (mediana sprememba -88,9 %) pri skupini bolnikov, ki je prejemala zdravilo Humira v primerjavi z -11,6 % (mediana sprememba -50,0 %) v skupini bolnikov, ki je prejemala placebo.
Tell your doctor as soon as possible if you notice any of the following 
Zdravniku čim prej povejte, če opazite kaj od naslednjega
the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. 
Zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih bolnikih, kadar odziv na imunomodulirajoča zdravila, vključno z metotreksatom, ni zadosten.
Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (Study HS-I). 
Večja izboljšanja v 12. tednu glede na izhodiščno vrednost v primerjavi s placebom so bila prikazana v kakovosti življenja, povezani s koži specifičnim zdravjem, merjena z dermatološkim indeksom kakovosti življenja (“Dermatology life quality index” (DLQI), v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenim z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (“Treatment Satisfaction Questionnaire - medication” (TSQM), v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v vprašalniku SF-36 (“Short Form Health Survey" (SF 36) v študiji HS-I).
The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA studies I, II and III. 
Odstotek bolnikov, zdravljenih z zdavilom Humira, ki so dosegli odziv 20, 50 in 70 po ACR, se je v študijah revmatoidnega artritisa I, II in III skladal.
≥ mNAPSI 75 (%) PGA-F clear/minimal and ≥2-grade improvement (%) 
PGA-F čisto/minimalno in ≥ izboljšanje za dve stopnji
After Week 2, patients in both adalimumab arms received 40 mg eow. 
Po 2. tednu so bolniki v obeh krakih z adalimumabom prejemali 40 mg vsak drugi teden.
• Your child and his/her doctor should pay special attention to signs of infection while your child is being treated with Humira. 
• Vaš otrok in njegov zdravnik morata biti posebej pozorna na znake okužbe, medtem ko se vaš otrok zdravi z zdravilom Humira.
Do not try to touch the needle. 
Ne poskušajte se dotakniti igle.
A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). 
Od bolnikov, deležnih ponovnega zdravljenja, jih je skupno 76,5 % (218/285) po 16 tednih ponovnega zdravljenja imelo odziv PGA "čisto" ali "minimalno", ne glede na to, ali je med prenehanjem uporabe prišlo do relapsa (69,1 % [123/178] bolnikov, pri katerih je med prenehanjem uporabe prišlo do relapsa, in 88,8 % [95/107] tistih, pri katerih ni prišlo do relapsa).
1 vial (0.8 ml sterile solution), 1 empty sterile injection syringe, 1 needle, 1 vial adapter and 2 alcohol pads. 
1 viala (0,8 ml sterilne raztopine), 1 prazna sterilna injekcijska brizga 1 igla, 1 adapter za vialo in 2 alkoholna zloženca.
Clinical remission is Mayo score ≤ 2 with no subscore > 1; 
Klinična remisija pomeni oceno Mayo ≤ 2 in nobene podocene > 1;
Holding the barrel of the pre-filled pen, press down slightly onto the injection site (holding in place without moving). 
Držite telo napolnjenega injekcijskega peresnika in peresnik rahlo pritisnite na mesto injiciranja (držite ga na mestu, ne da bi ga premikali).
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab antibodies during the 6 to 12 month period. 
Bolniki v študijah revmatoidnega artritisa I, II in III so bili v obdobju med 6. in 12. mesecem testirani za protitelesa proti adalimumabu.
In the Phase 3 trial of Humira in patients with paediatric Crohn's disease which evaluated efficacy and safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% (5/192) of patients of whom 4 were receiving concomitant immunosuppressants at baseline. 
V preskušanju faze 3 z zdravilom Humira pri bolnikih s pediatrično Crohnovo boleznijo, kjer so ocenjevali učinkovitost in varnost dveh telesni masi prilagojenih vzdrževalnih režimov odmerjanja, ki sta sledila telesni masi prilagojenemu začetnemu zdravljenju do 52 tednov zdravljenja, so se pojavila zvišanja ALT ≥ 3 x ULN pri 2,6 % (5/192) bolnikov, od katerih so štirje sočasno prejemali imunosupresive ob začetku preskušanja.
Humira is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years and enthesitis-related arthritis in children and adolescents aged 6 to 17 years. 
Zdravilo Humira se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri otrocih in mladostnikih, starih 2 do 17 let, in artritisa, povezanega z entezitisom pri otrocih in mladostnikih starih od 6 do 17 let.
2) Preparing the Humira dose for injection 
2) Priprava odmerka zdravila Humira za injiciranje
Do not press the plum activation button until properly positioned as this will result in discharge of medication. 
Ne pritisnite škrlatnega sprožilnega gumba, dokler peresnik ni pravilno nameščen, ker boste sicer iztisnili zdravilo.
• After the needle is in, let go of the skin you are holding 
• Ko je igla v koži, spustite kožo, ki jo držite
RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid arthritis who were  18 years old. 
V študiji revmatoidnega artritisa IV je bila v prvi vrsti ocenjena varnost pri 636 bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let.
These results suggest that some patients who have not responded by Week 4 benefit from continued maintenance therapy through Week 12. 
Ti rezultati nakazujejo, da nekaterim bolnikom, ki se ne odzovejo do 4. tedna, koristi nadaljevanje vzdrževalnega zdravljenja do
Available data suggest that clinical response is usually achieved within 2-8 weeks of treatment. 
Podatki, ki so na voljo, kažejo, da je klinični odziv po navadi dosežen v 2-8 tednih zdravljenja.
Clinical remission Clinical response (CR 
Klinična remisija Klinični odziv (CR
Taking these results into consideration, Humira is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2). 
Z upoštevanjem teh ugotovitev je zdravilo Humira priporočljivo uporabljati v kombinaciji z metotreksatom, kot monoterapijo pa pri bolnikih, za katere uporaba metotreksata ni primerna (glejte poglavje 4.2).
• Humira can be used during breast-feeding. 
• Zdravilo Humira se lahko uporablja med dojenjem.
Hold the pre-filled pen so that you can see the inspection window. 
Napolnjen injekcijski peresnik držite, tako da lahko vidite kontrolno okence.
Prescribers should exercise caution in considering the use of Humira in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of Humira should be considered if any of these disorders develop. 
Pri odločanju za uporabo zdravila Humira pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega ali perifernega živčevja je potrebna previdnost; če se razvije katera od teh bolezni, je treba razmisliti o prenehanju zdravljenja z zdravilom Humira.
Placebo (treatment withdrawal) N = 73 
Placebo (ukinitev zdravljenja) N = 73
673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to  2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open-label period of Study nr-axSpA II during which they received Humira 40 mg eow for 28 weeks. 
673 bolnikov z aktivnim nr-axSpA (srednja vrednost aktivnosti bolezni [BASDAI] je bila 7,0), ki so nezadostno reagirali na vsaj dva NSAID ali niso prenašali NSAID ali s kontraindikacijo za NSAID, je bilo vključenih v odprto fazo študije nr-axSpA II, v kateri so prejemali zdravilo Humira 40 mg vsak drugi teden 28 tednov.
the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. 
Zdravljenje hudega, aktivnega in progresivnega revmatoidnega artritisa pri odraslih, ki prej še niso dobivali metotreksata.
The conduct and results of these tests should be recorded on your Patient Reminder Card. 
Izvedbo in rezultate teh preiskav je treba zabeležiti na opozorilni kartici za bolnika.
Humira treated patients had significantly greater improvement at Week 12 which was maintained through Week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). 
Bolniki, ki so dobivali zdravilo Humira, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) SF36 in ASQoL (Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu - Ankylosing Spondylitis Quality of Life Questionnaire).
The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”). 
Kombinacija zdravila Humira in abatacepta ni priporočljiva (glejte poglavje 4.4 “Sočasna uporaba bioloških DMARDS ali antagonistov TNF”).
If you use more Humira than you should 
Če ste uporabili večji odmerek zdravila Humira, kot bi smeli